Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients

Introduction This study is to evaluate the association of polymorphisms of glutathione S-transferase P1 (GSTP1), copper-transporting P-type adenosine triphosphatase A (ATP7A) and X-ray repair cross-complementing group 1 (XRCC1) with the efficacy and toxicity of cisplatin-based treatment in advanced non-small cell lung cancer (NSCLC) patients. Materials and methods The outcomes of 97 advanced non-small cell lung cancer patients treated with cisplatin-based chemotherapy were estimated. GSTP1, ATP7A, and XRCC1 genetic polymorphisms were determined via polymerase chain reaction of restriction fragment length polymorphism (PCR–RFLP) and DNA sequencing. Association of the polymorphisms with the efficacy and toxicity of cisplatin was analyzed, respectively. Results Significant associations were observed between GSTP1 A313G and response rate (RR) ( p = 0.027), disease control rate (DCR) ( p = 0.019), and progression-free survival (PFS) ( p = 0.044), respectively. Patients with AG and GG of GSTP1 have notably lower risk of anemia ( p = 0.046). XRCC1 A1196G was associated with the incidence of lymphopenia ( p = 0.024) and diarrhea ( p = 0.020). ATP7A C2299G was not related with RR, DCR, PFS, and the risk of toxicity. Conclusions Advanced NSCLC patients with AA genotype of GSTP1 would obtain better curative effect followed with more risk of anemia when treated by cisplatin-based chemotherapy. ATP7A C2299G does not impact the efficacy and toxicity of cisplatin-based chemotherapy. XRCC1 1196A allele could predict the incidence of lymphopenia and diarrhea.